By Jeffrey A. Allen, MD Member, GBS|CIDP Foundation Global Medical Advisory Board CIDP as a named disease entity is now about 4 decades old. The laboratory data that helps define the disease, nerve conduction studies and in some cases cerebral spinal fluid and nerve biopsy, is even older; and the initial description of what has…Read More about Research in CIDP: Are we making progress?
David Saperstein, MD Co-Director GBS/CIDP Center of Excellence Phoenix Neurological Associates Phoenix, AZ Intravenous immunoglobulin (IVIg) is one of the main therapies used to treat CIDP. This therapy can be very effective but there are drawbacks. Some people experience headaches related to the intravenous infusions. Some people have difficulty with IV access. Also, the need…Read More about Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP
We are pleased to announce our 2018 Research Grant Awardees.Read More about 2018 Research Grant Finalists Announced
In March 2018 Congress passed an omnibus bill that finalized Fiscal Year 2018 appropriations. Guillain-Barré Syndrome was again listed as a condition eligible for study! Now is the time to begin applications for available grants. Below is more detailed information regarding applications and possible awards.Read More about Attention Researchers! GBS Deemed Eligible for Research Studies through Department of Defense Peer Review
On June 10, 2018 the GBS|CIDP Foundation International will be holding its 5th Annual New Jersey Walk & Roll. The event will be chaired by local resident, and Foundation volunteer, Susan Salzmann. Recently we had the pleasure of sitting down with Susan as she shared the complex story of her husband’s personal journey with CIDP….Read More about A Life and Legacy Dedicated to Research